Date: 2016-01-11
Type of information: Development agreement
Compound: large scale viral vector manufacturing platform
Company: Synpromics (UK) Cell and Gene Therapy Catapult (UK)
Therapeutic area: Technology - Services
Type agreement: development
Action mechanism:
Disease:
Details:
- • On January 11, 2016, Synpromics and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, announced the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and increasing the scale and efficiency of viral vector manufacturing.
- The collaboration will use Synpromics' synthetic promoter design technology, and the Cell Therapy Catapult's flexible manufacturing platform to create stable producer cell lines for the high titre and large scale manufacture of viral vectors. The work will be part funded by a £2m grant from Innovate UK, the UK’s innovation agency. This project will use synthetic biology to develop novel and controllable gene-expression promoters to drive the production of a much higher level of viral vector yield from new stable cell lines. This will allow the industry to produce vectors to much higher titres and with more efficiency, removing the current constraints associated with plasmid transfection of anchorage dependent cell lines. The project will run for three years, and will be focused on developing prototype cell lines to deliver industry relevant viral vectors, including Retrovirus, and Adeno Associated Virus. Synpromics will be responsible for the expression platform development with the Cell Therapy Catapult responsible for process industrialisation and control.
Financial terms:
Latest news:
Is general: Yes
